With respect to in vitro experiments, it is not surprising that the direct influence of iNOS inhibitors on lungs or pulmonary vasculature was investigated, because all current state-of-the-art medications, approved for PAH treatment, are targeted towards pulmonary vasodilatation. This evidence concerns the gene NOS2 and pulmonary arterial hypertension.